Business Wire

International Live Webinar on July 11: “Put Talent First: Practical Steps to Eliminate Gender Bias in Science”

Del

The Fondation IPSEN is happy to announce the organization of an international live webinar that will address practical issues of gender-based discrimination in Science. This webinar is organized by Science Journal (AAAS) in association with Fondation IPSEN. This event will be held on July 11st at 6 pm (CET) / 12 pm (Washington DC).

Free & anonymous registration:
http://www.sciencemag.org/custom-publishing/webinars

The #metoo movement spread on social media as a hashtag to help demonstrate the widespread prevalence of sexual assault and harassment in the workplace. As a result, it encouraged women to reveal the extent of problems. It has swept the entertainment industry, politics, and even Uber. Is science next? This live roundtable discussion will address the continuing problem of gender-based discrimination in science.

Our experts panel will examine the efforts being taken by scientific organizations, academic centers, and funding agencies to end gender bias in science. They will also consider the cultural changes needed in science to prevent and eradicate discrimination, including moving the narrative away from blaming the victim and excusing discriminatory behavior, and will highlight the responsibility of society. Through collective actions within the scientific community we wish to create gender equitable, nondiscriminatory and bias-free workplaces.

Speakers
Anna Han, Ph.D. (NIH, Bethesda, USA)
She is a senior behavioural scientist in the Office of the Director, Scientific Workforce Diversity, at the National Institutes of Health (NIH). Her work focuses on evidence-based approaches to enhance the diversity and social inclusion in the scientific workforce.

Kathryn Clancy, Ph.D. (University of Illinois, Urbana, USA)
She is an American biological anthropologist specialized in reproductive health. She is Associate Professor at the University of Illinois, in the Department of Anthropology. Her additional research and policy advocacy work focuses on sexual harassment in science and academia.

Isabelle Collet, Ph.D (University of Geneva, Switzerland)
She obtained her Ph.D. in Education from the University of Paris-Nanterre, France, in 2005, and the next year published the book, “Does computer science have gender?” based on her thesis work. She has served as a scientific expert on numerous gender-neutral education projects in STEM in Belgium, France, and Switzerland. Her research interests are focused on closing the gender gap in STEM (especially in IT) and developing strategies of inclusion for women in higher education.

Moderated by Shirley Malcolm, Ph.D. (Science/AAAS, Washington, USA)
Shirley Malcom is head of Education and Human Resources at AAAS. In this position she works to improve the quality and increase access to education and careers in STEM.

Science Journal (AAAS)
The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science as well as Science Translational Medicine, Science Signaling and Science Advances. AAAS was founded in 1848, and includes some 261 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of 1 million. The non-profit AAAS (www.aaas.org) is open to all and fulfils its mission to “advance science and serve society” not only by publishing the very best scientific research but also through initiatives in science policy, international programs and science education.
www.sciencemag.org

The Fondation IPSEN
Established in 1983 under the aegis of the Fondation de France, Fondation IPSEN seeks to holistically promote research in various therapeutic fields to improve human well-being and health. In this respect, the Foundation aims to facilitate the process of interdisciplinary groups of scientists and clinical practitioners from different countries, to promote the interactions needed between specialists in different fields of research, and to spread the knowledge to the general public.
www.fondation-ipsen.org

Contact information

Fondation IPSEN
Yannick TANGUY, Tel. : +33 (0)6 81187860
Project manager
E-mail : yannick.tanguy@ipsen.com
www.fondation-ipsen.org
Twitter: @scienceforpeople-FI
LinkedIn: Science for People-Fondation IPSEN
Facebook: Science for People
YouTube: Science for people

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science26.5.2019 07:00:00 CESTPressemelding

Nanopharmaceutics promises ground-breaking innovation in the development of medicines: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005014/en/ The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the University of Basel The commitment by Vifor Pharma and the University of Basel is aimed at ensuring Switzerland has the specialist knowledge and equipment needed to compete globally in this important emerging area of life sciences With this decision, Vifor Pharma is demonstrating its commitment to Switzerland as a world-leading location for pharmaceutical research and development Nanomedicines are playing an increasingly important role in the development of innovative new medications. These drugs are able to overcome specific cellular barriers in the human body with a view to targeting their effect even more precisely. Nanopharmacy therefore promises to help advance medic

XINHUANET: Promotion Event of The Most Beautiful Shooting Location in China Held During Cannes Film Festival25.5.2019 18:20:00 CESTPressemelding

On May 16 (local time), an event was held at the 72nd Cannes Film Festival to recommend China’s most beautiful shooting locations on the theme of “Fascinating China.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190525005008/en/ The representative from Cannes Convention Bureau (1st L), Michel Chevillon (C), vice president of the French Riviera Chamber of Commerce and Industry and head of hotel association, and Adeline CHAUVEAU (3rd R), officer in charge of film and television projects from French Embassy to China, pose for a group photo with the representatives from the cities awarded for "The most beautiful shooting location in China." (Photo: Business Wire) In the event, the Yellow Sea National Forest Park in Dongtai, Jiangsu Province, the One Hundred Mile Azalea Forest in Bijie, Guizhou Province, Siming District of Xiamen, Fujian Province, and the Li Autonomous County in Lingshui, Hainan Province were on the list. The p

Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference24.5.2019 14:00:00 CESTPressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida. KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were presented by Steven Dworetzky, Ph.D., Knopp’s Chief Scientific Officer, a longtime Kv7 researcher who led the group that first cloned the Kv7.2 and Kv7.3 genes during his former tenure with the Bristol-Myers Squibb Co. Dr. Dworetzky presented results demonstrating the in vitro nanomolar activity of KB-3061 and its significant seizure protection in the maximal electroshock mo

Accelerate Your Business in South Korea Through 2019 K-Startup Grand Challenge24.5.2019 10:20:00 CESTPressemelding

Entrepreneurs from across the globe should set their sights on participating in the 2019 K-Startup Grand Challenge. Supported by the Ministry of SMEs and Startups and National IT Industry Promotion Agency (NIPA) of South Korea, the initiative provides invaluable support and comprehensive resources to early age startups. Applications for the K-Startup Grand Challenge are currently being accepted through June 14, 2019. In order to advance in the program, teams must pass a regional audition. A judging panel of startup ecosystem experts and Korean accelerators will select 40 teams to participate in an enriching 3.5 month-long acceleration program in Korea. The selected teams will have exclusive access to free office space at the Startup Campus in Pangyo Techno Valley, one-on-one mentoring, information sessions, coaching on Korean and Asian business culture and the chance to attend insightful seminars on accounting regulations to tax laws, patents and more. Opportunities for networking with

New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting24.5.2019 05:00:00 CESTPressemelding

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx®), liposomal irinotecan (Onivyde®), and lanreotide autogel (Somatuline®, marketed as Somatuline Depot® in the United States) will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting takes place in Chicago, Illinois, U.S., 31 May–4 June 2019; data featuring Ipsen medicines includes: New data from the Phase 3 CELESTIAL trial on the association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma Overview of the Phase 3 COSMIC-312 trial of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma who have not received previous systemic anticancer therapy First Phase 2 data from the CaboGIST study (trial 1317) from the European Organization for Research and Treatment of

The Posiflex Group Showcases an Ecosystem of Connected Solution Endpoints with IoT Remote Monitoring at Computex 201924.5.2019 01:00:00 CESTPressemelding

For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include: Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems Smart Medical Displays with gesture controls from Portwell Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology. This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order sta